Sofosbuvir
Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used to treat hepatitis C. It is taken by mouth.
Clinical data | |
---|---|
Trade names | Sovaldi, others |
Other names | PSI-7977; GS-7977 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614014 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | HCV polymerase inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 92% |
Protein binding | 61–65% |
Metabolism | Quickly activated to triphosphate (CatA/CES1, HIST1, phosphorylation) |
Elimination half-life | 0.4 hrs (sofosbuvir) 27 hrs (inactive metabolite GS-331007) |
Excretion | 80% urine, 14% feces (mostly as GS-331007) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.224.393 |
Chemical and physical data | |
Formula | C22H29FN3O9P |
Molar mass | 529.458 g·mol−1 |
3D model (JSmol) | |
| |
|
Common side effects include fatigue, headache, nausea, and trouble sleeping. Side effects are generally more common in interferon-containing regimens.: 7 Sofosbuvir may reactivate hepatitis B in those who have been previously infected. In combination with ledipasvir, daclatasvir or simeprevir, it is not recommended with amiodarone due to the risk of an abnormally slow heartbeat. Sofosbuvir is in the nucleotide analog family of medications and works by blocking the hepatitis C NS5B protein.
Sofosbuvir was discovered in 2007 and approved for medical use in the United States in 2013. It is on the World Health Organization's List of Essential Medicines.